GlassScriptPhysician profile
Thomas A Krefft
NPI 1528068327
$21,577.27
in general payments reported to CMS, 2019-2025
51 companies · $16.89 in 2025
The $16.89 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,271 · 2020: $13K · 2021: $4,265 · 2022: $1,893 · 2023: $77.42 · 2024: $76.17 · 2025: $16.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,235.18 | 2019-2021 | |
| Biogen, INC. | $674.89 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $616.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $555.50 | 2019-2024 | |
| Grifols USA, LLC | $514.84 | 2019-2022 | |
| Ucb, INC. | $510.56 | 2019-2022 | |
| Lilly USA, LLC | $448.20 | 2019-2022 | |
| Abbvie INC. | $428.13 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $327.25 | 2019-2021 | |
| Genzyme Corporation | $324.87 | 2019-2022 | |
| Amgen INC. | $283.13 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $261.99 | 2019-2021 | |
| Emd Serono, INC. | $259.65 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $247.79 | 2019-2022 | |
| Acorda Therapeutics, INC | $219.70 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Krefft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.